| PRECLINICAL | evidence | Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Prospective Comparative Analysis of Synchronous Abdominoplasty and Mastopexy in Bariatric and Nonbariatric Massive Weight Loss Patients: Highlighting the Rising Trend of GLP-1 Analog Use. | Tirzepatide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Use (and Potential for Abuse) of Glucagon-Like Peptide-1 Medications Among Individuals with Eating Disorders: Empirical Review and Clinical Guidance. | Zepbound | — | 2026-03-01 |
| PRECLINICAL | evidence | Beyond weight loss: Effect of GLP-1 receptor agonist therapy on the urological health. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Head-to-head comparison of tirzepatide and semaglutide for weight loss: A systematic review and meta-analysis. | Tirzepatide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Weight regain after bariatric surgery: A framework for management. | Tirzepatide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Obesity medications and acquired hypothalamic obesity in adults: A two-case experience. | Tirzepatide | — | 2026-03-01 |
| PRECLINICAL | evidence | Real-world 6-month persistence, adherence, and effectiveness of GLP-1 medications for overweight and obesity in a Medicaid population. | Zepbound | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Trends in 1-year persistence and adherence among initiators of high-potency, weight loss-indicated glucagon-like peptide 1 receptor agonists. | Zepbound | — | 2026-03-01 |
| PRECLINICAL | evidence | [Obesity: novel pharmacological treatments]. | Tirzepatide | Weight & fat loss | 2026-03-01 |
| PRECLINICAL | evidence | Glucose Control and Continuous Glucose Monitoring Metrics During 12 Months of Treatment with Tirzepatide in Overweight or Obese Patients with Type 1 Diabetes. | Tirzepatide | Glycemic control | 2026-03-01 |
| PRECLINICAL | evidence | Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits. | Tirzepatide | Glycemic control | 2026-02-28 |
| PRECLINICAL | evidence | Comparative efficacy of tirzepatide and glucagon-like peptide-1 receptor agonists on cardiovascular outcomes in patients with type 2 diabetes: a systematic review and network meta-analysis. | Tirzepatide | Glycemic control | 2026-02-27 |
| PRECLINICAL | evidence | Psychiatric Adverse Events and Administration Challenges Associated with GLP-1 Receptor Agonists for Weight Loss: A Real-World Analysis. | Tirzepatide | — | 2026-02-26 |
| PRECLINICAL | evidence | Brca1 heterozygosity leads to hepatic steatosis in male and female mice despite sexually dimorphic effects on systemic metabolism. | Tirzepatide | — | 2026-02-26 |
| PRECLINICAL | evidence | Adverse events associated with tirzepatide: a focus on subgroup-specific differences. | Tirzepatide | — | 2026-02-26 |
| PRECLINICAL | evidence | Mounjaro: Online pharmacy is investigated after supplying fake weight loss pens. | Mounjaro | — | 2026-02-25 |
| PRECLINICAL | evidence | Mounjaro: GP incentive to prescribe weight loss jabs won't tackle rollout problems, experts warn. | Mounjaro | — | 2026-02-24 |
| PRECLINICAL | evidence | Obesity medications and precision nutrition: synergistic interventions and integrated approach in obesity management. | Tirzepatide | Weight & fat loss | 2026-02-24 |
| PRECLINICAL | evidence | Cardiovascular benefits of obesity therapies: an overview of obesity medicines and metabolic bariatric surgery. | Tirzepatide | — | 2026-02-23 |
| PRECLINICAL | evidence | Treatment preferences for comorbid obesity and obstructive sleep apnea (PRO-CON OSA) survey: Patient and provider preferences for CPAP and/or tirzepatide. | Tirzepatide | — | 2026-02-23 |
| PRECLINICAL | evidence | Overview of Diabetes Medications: Traditional and New-Generation Agents and Their Off-Label Use for Weight Loss. | Tirzepatide | — | 2026-02-23 |
| PRECLINICAL | evidence | Probable Tirzepatide-Induced Rhabdomyolysis in an HIV-Positive Patient. | Tirzepatide | — | 2026-02-23 |
| PRECLINICAL | evidence | Obesity in Type 1 Diabetes: Moving Beyond the "Lean" Disease Paradigm to Understand Risk, Complications, and Treatment. | Tirzepatide | — | 2026-02-21 |
| PRECLINICAL | evidence | Effect of GLP-1 Receptor Agonists in Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-02-21 |
| PRECLINICAL | evidence | Incretin-Based Dual and Triple Agonists in Overweight or Obese Individuals: A Systematic Review and Meta-Analysis. | Tirzepatide | — | 2026-02-19 |
| PRECLINICAL | evidence | Efficacy and safety of anti-prediabetic drugs in patients with prediabetes: a Bayesian network meta-analysis. | Tirzepatide | Glycemic control | 2026-02-19 |
| PRECLINICAL | evidence | Comparative efficacy of GLP-1 RA, tirzepatide and SGLT-2 inhibitors in metabolic liver disease: A network meta-analysis. | Tirzepatide | — | 2026-02-17 |
| PRECLINICAL | evidence | GLP-1 and the cardiovascular system. | Tirzepatide | Lipid & cardiovascular markers | 2026-02-16 |
| PRECLINICAL | evidence | In brief: Removal of suicidality warning from GLP-1 Agonists for weight management. | Zepbound | — | 2026-02-16 |
| PRECLINICAL | evidence | Early glucagon-like peptide-1 receptor agonist use after myocardial infarction in patients with type 2 diabetes. | Tirzepatide | Glycemic control | 2026-02-15 |
| PRECLINICAL | evidence | Compounded Semaglutide and Tirzepatide Products Use Unique Formulations but Efficacy and Safety Largely Unknown. | Tirzepatide | — | 2026-02-14 |
| PRECLINICAL | evidence | A Narrative Review on GLP-1 Receptor Agonists for Obesity in Older Women: Maximizing Weight Loss While Preserving Lean Mass. | Tirzepatide | — | 2026-02-14 |
| PRECLINICAL | evidence | Cardio-Obesity and Therapeutic Advances: Intersections Between Excess Adiposity, Cardiovascular Risk, and Pharmacologic Interventions. | Tirzepatide | Weight & fat loss | 2026-02-13 |
| PRECLINICAL | evidence | Comparing Telepharmacy to Conventional Pharmacy Care: An Economic Evaluation. | Zepbound | — | 2026-02-13 |
| PRECLINICAL | evidence | The promoting roles of GLP1R and GIPR in stemness maintenance and multiple lineage-specific differentiation of PDLSCs. | Tirzepatide | — | 2026-02-11 |
| PRECLINICAL | evidence | Fixing the food environment: beyond weight-loss drugs. | Tirzepatide | Weight & fat loss | 2026-02-06 |
| PRECLINICAL | evidence | A Convergent Hybrid Gram-Scale Synthesis of Tirzepatide: Tangential Flow Filtration Assisted Native Chemical Ligation-Desulfurization Approach. | Tirzepatide | — | 2026-02-02 |
| PRECLINICAL | evidence | A Rare Case of Tirzepatide-Associated Immune Thrombocytopenia. | Mounjaro | — | 2026-02-01 |
| PRECLINICAL | evidence | Impact of GLP-1 receptor agonists on stroke, subarachnoid hemorrhage, and intracerebral hemorrhage: a propensity-matched multi-institutional cohort study. | Tirzepatide | Neuroprotection | 2026-02-01 |
| PRECLINICAL | evidence | GLP-1RAs and tirzepatide may reduce heart failure risk in obese but not in non-obese patients with cardiovascular or renal disease: A systematic review and meta-analysis. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Ethical Considerations in the Use of Weight Loss Medications. | Tirzepatide | Weight & fat loss | 2026-02-01 |
| PRECLINICAL | evidence | Comment on "Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes". | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | EBM BLS: Tirzepatide Remains Effective for Obesity Treatment and Diabetes Prevention at 3 Years of Follow-up. | Tirzepatide | — | 2026-02-01 |
| PRECLINICAL | evidence | Anti-inflammatory effects of tirzepatide: a systematic review and meta-analysis. | Tirzepatide | Inflammation | 2026-02-01 |
| PRECLINICAL | evidence | Safety and effectiveness of tirzepatide during Ramadan fasting: Real-world evidence from patients with type 2 diabetes in Bangladesh. | Tirzepatide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | Socioeconomic Factors and Initiation of Semaglutide or Tirzepatide Among Medicare Beneficiaries With Type 2 Diabetes. | Tirzepatide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | Meta-analysis of clinically available pharmacotherapy of biopsy confirmed metabolic dysfunction associated steatohepatitis (MASH). | Tirzepatide | Liver health | 2026-02-01 |
| PRECLINICAL | evidence | Risk for Cancer With Glucagon-Like Peptide-1 Receptor Agonists and Dual Agonists : A Systematic Review and Meta-analysis. | Tirzepatide | Glycemic control | 2026-02-01 |
| PRECLINICAL | evidence | From one-size-fits-all to phenotype-based pharmacotherapy: How far are we in obesity management? | Tirzepatide | Weight & fat loss | 2026-02-01 |